Which has better earnings & valuation, IRMD or ELMD?

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 14.38 $22.48M $1.83 51.54 Electromed $71.75M 4.63 $5.15M $1.17 34.32

Is IRMD or ELMD more profitable?

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 27.36% 24.48% 21.25% Electromed 11.34% 15.71% 13.37%

Does the media refer more to IRMD or ELMD?

In the previous week, iRadimed had 3 more articles in the media than Electromed. MarketBeat recorded 5 mentions for iRadimed and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat iRadimed's score of 0.78 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ELMD or TNDM?

In the previous week, Tandem Diabetes Care had 7 more articles in the media than Electromed. MarketBeat recorded 9 mentions for Tandem Diabetes Care and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Tandem Diabetes Care's score of 1.37 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tandem Diabetes Care 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ELMD or AVNS?

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 6.62%. Given Electromed's stronger consensus rating and higher probable upside, equities analysts plainly believe Electromed is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer ELMD or AVNS?

In the previous week, Avanos Medical had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Avanos Medical and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Avanos Medical's score of 0.36 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avanos Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, BVS or ELMD?

Bioventus has higher revenue and earnings than Electromed. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.90 $22.73M $0.41 32.00 Electromed $71.75M 4.63 $5.15M $1.17 34.32

Is BVS or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Electromed's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Electromed 11.34% 15.71% 13.37%

Does the media refer more to BVS or ELMD?

In the previous week, Bioventus had 5 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Bioventus and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Bioventus' score of 1.06 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ELMD or DRTS?

In the previous week, Alpha Tau Medical had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Alpha Tau Medical and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Alpha Tau Medical's score of 0.23 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alpha Tau Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Electromed (ELMD) Competitors

$40.16 +0.68 (+1.72%)

Closing price 07/29/2026 04:00 PM Eastern

Extended Trading

$40.20 +0.04 (+0.10%)

As of 07/29/2026 07:34 PM Eastern

Compare

ELMD vs. IRMD, TNDM, AVNS, BVS, and DRTS

Should you buy Electromed stock or one of its competitors? MarketBeat compares Electromed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Electromed include iRadimed (IRMD), Tandem Diabetes Care (TNDM), Avanos Medical (AVNS), Bioventus (BVS), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.

How does Electromed compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Electromed	11.34%	15.71%	13.37%

92.3% of iRadimed shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	14.38	$22.48M	$1.83	51.54
Electromed	$71.75M	4.63	$5.15M	$1.17	34.32

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 27.23%. Electromed has a consensus price target of $37.50, indicating a potential downside of 6.62%. Given iRadimed's stronger consensus rating and higher possible upside, equities research analysts plainly believe iRadimed is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, iRadimed had 3 more articles in the media than Electromed. MarketBeat recorded 5 mentions for iRadimed and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat iRadimed's score of 0.78 indicating that Electromed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Electromed has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

iRadimed beats Electromed on 14 of the 16 factors compared between the two stocks.

How does Electromed compare to Tandem Diabetes Care?

Electromed (NYSE:ELMD) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Electromed has a net margin of 11.34% compared to Tandem Diabetes Care's net margin of -9.20%. Electromed's return on equity of 15.71% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Electromed has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.63	$5.15M	$1.17	34.32
Tandem Diabetes Care	$1.01B	1.26	-$204.71M	-$1.40	N/A

Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Electromed currently has a consensus price target of $37.50, suggesting a potential downside of 6.62%. Tandem Diabetes Care has a consensus price target of $28.73, suggesting a potential upside of 54.52%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Tandem Diabetes Care had 7 more articles in the media than Electromed. MarketBeat recorded 9 mentions for Tandem Diabetes Care and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Tandem Diabetes Care's score of 1.37 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tandem Diabetes Care	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Electromed beats Tandem Diabetes Care on 11 of the 17 factors compared between the two stocks.

How does Electromed compare to Avanos Medical?

Electromed (NYSE:ELMD) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

40.8% of Electromed shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 2.3% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 6.62%. Given Electromed's stronger consensus rating and higher probable upside, equities analysts plainly believe Electromed is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Electromed has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

In the previous week, Avanos Medical had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Avanos Medical and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Avanos Medical's score of 0.36 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avanos Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Electromed has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.63	$5.15M	$1.17	34.32
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

Electromed has a net margin of 11.34% compared to Avanos Medical's net margin of -10.39%. Electromed's return on equity of 15.71% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Avanos Medical	-10.39%	5.39%	3.97%

Summary

Electromed beats Avanos Medical on 12 of the 16 factors compared between the two stocks.

How does Electromed compare to Bioventus?

Bioventus (NASDAQ:BVS) and Electromed (NYSE:ELMD) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Electromed has a net margin of 11.34% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Electromed	11.34%	15.71%	13.37%

Bioventus has higher revenue and earnings than Electromed. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.90	$22.73M	$0.41	32.00
Electromed	$71.75M	4.63	$5.15M	$1.17	34.32

62.9% of Bioventus shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bioventus presently has a consensus price target of $14.75, suggesting a potential upside of 12.42%. Electromed has a consensus price target of $37.50, suggesting a potential downside of 6.62%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Bioventus had 5 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Bioventus and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Bioventus' score of 1.06 indicating that Electromed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Electromed has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Bioventus beats Electromed on 11 of the 17 factors compared between the two stocks.

How does Electromed compare to Alpha Tau Medical?

Electromed (NYSE:ELMD) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Electromed has a net margin of 11.34% compared to Alpha Tau Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Alpha Tau Medical	N/A	-73.23%	-52.90%

Electromed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.63	$5.15M	$1.17	34.32
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

In the previous week, Alpha Tau Medical had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Alpha Tau Medical and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Alpha Tau Medical's score of 0.23 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alpha Tau Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

40.8% of Electromed shares are held by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are held by institutional investors. 10.5% of Electromed shares are held by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Electromed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Electromed presently has a consensus price target of $37.50, indicating a potential downside of 6.62%. Alpha Tau Medical has a consensus price target of $12.60, indicating a potential upside of 12.70%. Given Alpha Tau Medical's higher probable upside, analysts clearly believe Alpha Tau Medical is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Electromed beats Alpha Tau Medical on 10 of the 15 factors compared between the two stocks.

Get Electromed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELMD vs. The Competition

Export

Metric	Electromed	Electromedical equipment Industry	Medical Sector	NYSE Exchange
Market Cap	$332.53M	$70.84M	$7.07B	$23.80B
Dividend Yield	N/A	N/A	2.65%	4.18%
P/E Ratio	53.55	8.94	27.41	30.53
Price / Sales	4.63	191.79	517.16	18.91
Price / Cash	41.36	41.36	51.57	32.22
Price / Book	7.87	4.40	9.93	4.76
Net Income	$5.15M	-$5.50M	$3.60B	$1.07B
7 Day Performance	5.19%	-2.97%	-1.41%	0.53%
1 Month Performance	-5.06%	-13.96%	-4.40%	1.45%
1 Year Performance	114.87%	70.70%	20.20%	15.53%

Electromed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELMD Electromed	1.2055 of 5 stars	$40.16 +1.7%	$37.50 -6.6%	+113.4%	$332.53M	$71.75M	53.55	160
IRMD iRadimed	2.3534 of 5 stars	$95.78 +0.7%	$120.00 +25.3%	+63.2%	$1.22B	$83.81M	52.34	110	Upcoming Earnings
TNDM Tandem Diabetes Care	2.863 of 5 stars	$17.57 +2.4%	$28.73 +63.5%	+11.4%	$1.20B	$1.01B	N/A	2,500	News Coverage Positive News Upcoming Earnings Analyst Forecast
AVNS Avanos Medical	0.9121 of 5 stars	$24.99 +0.0%	N/A	N/A	$1.17B	$701.20M	N/A	2,287	News Coverage Positive News Upcoming Earnings High Trading Volume
BVS Bioventus	3.5955 of 5 stars	$12.95 +4.0%	$14.75 +13.9%	+100.6%	$1.08B	$568.09M	31.57	1,200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELMD) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Electromed (ELMD) Competitors

ELMD vs. IRMD, TNDM, AVNS, BVS, and DRTS

How does Electromed compare to iRadimed?

Summary

How does Electromed compare to Tandem Diabetes Care?

Summary

How does Electromed compare to Avanos Medical?

Summary

How does Electromed compare to Bioventus?

Summary

How does Electromed compare to Alpha Tau Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Electromed (ELMD) Competitors

ELMD vs. IRMD, TNDM, AVNS, BVS, and DRTS

How does Electromed compare to iRadimed?

Is IRMD or ELMD more profitable?

Do institutionals and insiders believe in IRMD or ELMD?

Which has better earnings & valuation, IRMD or ELMD?

Do analysts recommend IRMD or ELMD?

Does the media refer more to IRMD or ELMD?

Which has more volatility & risk, IRMD or ELMD?

Summary

How does Electromed compare to Tandem Diabetes Care?

Is ELMD or TNDM more profitable?

Which has better earnings and valuation, ELMD or TNDM?

Which has more volatility and risk, ELMD or TNDM?

Do analysts prefer ELMD or TNDM?

Does the media prefer ELMD or TNDM?

Do institutionals and insiders hold more shares of ELMD or TNDM?

Summary

How does Electromed compare to Avanos Medical?

Do institutionals & insiders believe in ELMD or AVNS?

Do analysts recommend ELMD or AVNS?

Which has more risk and volatility, ELMD or AVNS?

Does the media prefer ELMD or AVNS?

Which has stronger earnings and valuation, ELMD or AVNS?

Is ELMD or AVNS more profitable?

Summary

How does Electromed compare to Bioventus?

Is BVS or ELMD more profitable?

Which has stronger valuation & earnings, BVS or ELMD?

Do institutionals & insiders hold more shares of BVS or ELMD?

Do analysts rate BVS or ELMD?

Does the media refer more to BVS or ELMD?

Which has more risk & volatility, BVS or ELMD?

Summary

How does Electromed compare to Alpha Tau Medical?

Is ELMD or DRTS more profitable?

Which has better earnings and valuation, ELMD or DRTS?

Does the media prefer ELMD or DRTS?

Do institutionals and insiders hold more shares of ELMD or DRTS?

Which has more volatility & risk, ELMD or DRTS?

Do analysts rate ELMD or DRTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools